Drug intelligence / Profile preview

yuxunafen

Development stage: Phase 1
Lead developer: Yangtze River Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Yuxunafen (also known as YR-290) is a small molecule phosphodiesterase type 5 (PDE5) inhibitor developed by Yangtze River Pharmaceutical Group for the treatment of erectile dysfunction (ED). As a member of the "-nafil" class of drugs, it works by selectively inhibiting the PDE5 enzyme in the corpus cavernosum, which prevents the degradation of cyclic guanosine monophosphate (cGMP). Elevated levels of cGMP lead to smooth muscle relaxation and increased blood flow to the penis, facilitating an erection in response to sexual stimulation. Yuxunafen is currently in Phase 1 clinical development in China, where it is being evaluated for its safety, pharmacokinetics, and pharmacodynamic effects on penile rigidity using RigiScan monitoring.

Other names: yuxunafen hydrochloride育勋那非

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on yuxunafen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yuxunafen.